stockportfolio.pro
Stocks / ILMN vs MRNA
ILMN vs MRNA
Illumina, Inc. and Moderna, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
ILMN is the larger company ($24.7B vs $24.5B). On the fundamentals, MRNA grows revenue faster (19.3% vs 6.0%); ILMN earns a higher net margin (19.6% vs -145.2%); ILMN has the stronger return on equity (31.2% vs -32.6%). Full numbers below — the stronger figure on each row is in green.
| Illumina, Inc. (ILMN) | Moderna, Inc. (MRNA) | |
|---|---|---|
| Market cap | $24.7B | $24.5B |
| Revenue (latest FY) | $4.34B | $1.94B |
| Net income (latest FY) | $850.00M | $-2.82B |
| Revenue growth (5y CAGR) | 6.0% | 19.3% |
| Net margin | 19.6% | -145.2% |
| Return on equity | 31.2% | -32.6% |
| P/E ratio | 29.6 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 7 | 2 |
| Positive free cash flow | Yes | No |
Compare with another company:
See the full ILMN vs MRNA breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open ILMN's full financials → Open MRNA's full financials →More comparisons
Frequently asked questions
Which is bigger, ILMN or MRNA?
Illumina, Inc. is larger by market capitalization — $24.7B versus $24.5B.
Which grows faster, ILMN or MRNA?
Over the last five fiscal years, Moderna, Inc. grew revenue faster — 19.3%/yr versus 6.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.